Thus, RGS2 is potent therapeutic target for cardiovascular diseases and future progress in the development of this class of drugs and Gαq-RGS2 signaling inhibitors for treatment of cardiovascular diseases is crucial and beneficial. This evidence concerns the gene GNAQ and cardiovascular disorder.